**AMEDEO Bladder Cancer: 2025-10-13**

**A. Coming soon: The San Dao Trilogy**

**B. Your Personal Amedeo Web Page**

**- For Computer:** [**https://amedeo.com/summary/px.php?table=blc&cid=267327**](https://amedeo.com/summary/px.php?table=blc&cid=267327)

**- For Smartphone:** [**https://m.amedeo.com/p12.php?table=blc&cid=267327**](https://m.amedeo.com/p12.php?table=blc&cid=267327)

**C. Your Amedeo Recommendation Code**

**Share it with your colleagues and students to help them stay updated:**

**6b5a2cdc883f560**

**Best regards,**

**Bernd Sebastian Kamps, M.D.**

[**http://linkedin.com/in/bskamps**](http://linkedin.com/in/bskamps)

\*\*\* Single Articles \*\*\*

1. CELIK M, Polat ME, Karaaslan M, Odabas O, et al.

Prediction of recurrence using hematologic and urinary markers in intravesical

Bacillus calmette Guerin treated bladder cancer.

Sci Rep. 2025;15:35415.

PubMed: <https://www.amedeo.com/p2.php?id=41073500&s=blc&pm=1462f940041c1dd>

ABSTRACT available

Share: <https://m.amedeo.com/41073500>

2. MA TS, He HY.

[The application and advances of immunohistochemistry in the diagnosis and

differential diagnosis of bladder tumors].

Zhonghua Bing Li Xue Za Zhi. 2025;54:1110-1113.

PubMed: <https://www.amedeo.com/p2.php?id=41073292&s=blc&pm=1462f940041c1dd>

Share: <https://m.amedeo.com/41073292>

3. RADIF D, Lindskrog SV, Nordentoft I, Birkenkamp-Demtroder K, et al.

The Impact of Kidney, Liver, and Immune Function on Circulating Tumor DNA

Detection in Muscle-invasive Bladder Cancer.

Eur Urol Oncol. 2025 Oct 9:S2588-9311(25)00246-9. doi: 10.1016/j.euo.2025.

PubMed: <https://www.amedeo.com/p2.php?id=41073166&s=blc&pm=1462f940041c1dd>

ABSTRACT available

Share: <https://m.amedeo.com/41073166>

4. COLONNA G, Liesker D, M WB, Taurino M, et al.

Clinical Characteristics and Management of Infective Native Arterial Aneurysms

Associated with BCG Therapy for Bladder Cancer.

Ann Vasc Surg. 2025 Oct 8:S0890-5096(25)00659-4. doi: 10.1016/j.avsg.2025.

PubMed: <https://www.amedeo.com/p2.php?id=41072608&s=blc&pm=1462f940041c1dd>

ABSTRACT available

Share: <https://m.amedeo.com/41072608>

5. ITO H, Koyama T, Tanahara S, Toda D, et al.

MRI findings of granulomatous prostatitis induced by intravesical Bacillus

Calmette-Guerin treatment for bladder cancer: a comparison with prostate cancer.

Jpn J Radiol. 2025 Oct 10. doi: 10.1007/s11604-025-01871.

PubMed: <https://www.amedeo.com/p2.php?id=41071449&s=blc&pm=1462f940041c1dd>

ABSTRACT available

Share: <https://m.amedeo.com/41071449>

6. TOKUDA PJK, Aizawa R, Iramina H, Ogata T, et al.

Online adaptive radiation therapy for muscle-invasive bladder cancer:

short-course and high-precision definitive treatment for elderly or medically

fragile patients.

Jpn J Radiol. 2025 Oct 10. doi: 10.1007/s11604-025-01885.

PubMed: <https://www.amedeo.com/p2.php?id=41071448&s=blc&pm=1462f940041c1dd>

ABSTRACT available

Share: <https://m.amedeo.com/41071448>

7. MA Z, Hao Y, He W, Xie X, et al.

Comprehensive investigation identifies CPSF3 as a novel prognostic and oncogenic

biomarker in bladder cancer.

Discov Oncol. 2025;16:1847.

PubMed: <https://www.amedeo.com/p2.php?id=41071397&s=blc&pm=1462f940041c1dd>

ABSTRACT available

Share: <https://m.amedeo.com/41071397>

8. ZHANG EZ, Millot JC, Balasubramanian A, Davis L, et al.

Persistent Sex Disparities in Bladder Cancer Diagnosis, an Analysis of National

Trends from 2012 to 2021.

Urol Pract. 2025 Oct 10:101097UPJ0000000000000904.

PubMed: <https://www.amedeo.com/p2.php?id=41071039&s=blc&pm=1462f940041c1dd>

ABSTRACT available

Share: <https://m.amedeo.com/41071039>

9. WANG S, Ye D, Yang L, Cheng F, et al.

Distinct Clinicopathological Features of HER2-Negative, HER2-Low, and

HER2-Overexpressing Urothelial Carcinoma in a Large Chinese Cohort.

Cancer Med. 2025;14:e71289.

PubMed: <https://www.amedeo.com/p2.php?id=41070976&s=blc&pm=1462f940041c1dd>

ABSTRACT available

Share: <https://m.amedeo.com/41070976>

10. MEYERS HM, Sharma J, Abdellatef AA, You M, et al.

Differential Expression of One-Carbon Pathway Enzyme ALDH1L1 Is Linked to

Tumorigenicity of Low-Grade Bladder Cancer Cells Through Metabolic Reprogramming.

Cancer Med. 2025;14:e71291.

PubMed: <https://www.amedeo.com/p2.php?id=41070972&s=blc&pm=1462f940041c1dd>

ABSTRACT available

Share: <https://m.amedeo.com/41070972>

11. KIDESS M, Ebner B, Volz Y, Hermans J, et al.

[Therapy of non-muscle-invasive Bladder Cancer].

MMW Fortschr Med. 2025;167:40-41.

PubMed: <https://www.amedeo.com/p2.php?id=41068396&s=blc&pm=1462f940041c1dd>

Share: <https://m.amedeo.com/41068396>

12. MOLINA-CERRILLO J, Catto J, Kamat AM, Necchi A, et al.

Revisiting Neoadjuvant Chemotherapy in Cisplatin-eligible Muscle-invasive Bladder

Cancer.

Eur Urol Oncol. 2025 Oct 8:S2588-9311(25)00242-1. doi: 10.1016/j.euo.2025.

PubMed: <https://www.amedeo.com/p2.php?id=41068039&s=blc&pm=1462f940041c1dd>

ABSTRACT available

Share: <https://m.amedeo.com/41068039>

13. KAWAHARA T, Nitta S, Shiga M, Nagumo Y, et al.

Second opinions and pathological review impact the clinical management of

patients with muscle-invasive bladder cancer.

World J Urol. 2025;43:602.

PubMed: <https://www.amedeo.com/p2.php?id=41065838&s=blc&pm=1462f940041c1dd>

ABSTRACT available

Share: <https://m.amedeo.com/41065838>

14. LIU H, Chen J, Zhu Q, Liu H, et al.

Efficacy of Disitamab Vedotin and Immune Profiles in High-Risk

Non-Muscle-Invasive Bladder Cancer With HER2 Overexpression.

MedComm (2020). 2025;6:e70427.

PubMed: <https://www.amedeo.com/p2.php?id=41064127&s=blc&pm=1462f940041c1dd>

Share: <https://m.amedeo.com/41064127>

15. HUSSAIN H, Reid U, Nagtode S, Shameem F, et al.

Macroplastique, a urethral bulking agent for stress urinary incontinence

mimicking a bladder tumour.

BMJ Case Rep. 2025;18:e263166.

PubMed: <https://www.amedeo.com/p2.php?id=41062122&s=blc&pm=1462f940041c1dd>

ABSTRACT available

Share: <https://m.amedeo.com/41062122>

16. RETRACTION: Examining the Causal Association between Psoriasis and Bladder

Cancer: A Two-sample Mendelian Randomization Analysis.

Skin Res Technol. 2025;31:e70252.

PubMed: <https://www.amedeo.com/p2.php?id=41059907&s=blc&pm=1462f940041c1dd>

Share: <https://m.amedeo.com/41059907>

17. SUGINO Y, Bao X, Sekito S, Miyachi S, et al.

Zebrafish Xenograft Model for Predicting Cisplatin Efficacy in Muscle-Invasive

Bladder Cancer.

Cancer Sci. 2025 Oct 8. doi: 10.1111/cas.70217.

PubMed: <https://www.amedeo.com/p2.php?id=41059675&s=blc&pm=1462f940041c1dd>

ABSTRACT available

Share: <https://m.amedeo.com/41059675>

18. MAQBOOL A, Aziz W, Iqbal S, Ather MH, et al.

Effectiveness of Video-Based Instructions on Urostomy Self-Care in Patients

Undergoing Radical Cystectomy with Ileal Conduit Urinary Diversion.

J Coll Physicians Surg Pak. 2025;35:1345-1349.

PubMed: <https://www.amedeo.com/p2.php?id=41058295&s=blc&pm=1462f940041c1dd>

ABSTRACT available

Share: <https://m.amedeo.com/41058295>

19. TONG H, Sun Y, He W.

Commentary on "Complex causal association between immune cell phenotypes and

bladder cancer: a mendelian randomization and mediation study".

Int J Surg. 2025 Oct 7. doi: 10.1097/JS9.0000000000003587.

PubMed: <https://www.amedeo.com/p2.php?id=41056009&s=blc&pm=1462f940041c1dd>

Share: <https://m.amedeo.com/41056009>

20. DULF DV, Ravegnini G, Giorgi FM, Burnar AL, et al.

The miRNA-immune axis in bladder cancer: systematic evidence for a new era of

immunotherapy precision.

Front Immunol. 2025;16:1639334.

PubMed: <https://www.amedeo.com/p2.php?id=41050687&s=blc&pm=1462f940041c1dd>

ABSTRACT available

Share: <https://m.amedeo.com/41050687>

21. MARTINSON T, Hare CB, Kirmaier A, Presti JC, et al.

Disseminated BCGosis After Intravesical BCG Installation for Bladder Cancer.

Case Rep Infect Dis. 2025;2025:9532859.

PubMed: <https://www.amedeo.com/p2.php?id=41050560&s=blc&pm=1462f940041c1dd>

ABSTRACT available

Share: <https://m.amedeo.com/41050560>

22. ZHANG L, Li F, Liu L, Cao J, et al.

Prevalence and prognostic value of sarcopenia in patients with bladder cancer

undergoing radical cystectomy: a systematic review and meta-analysis.

Front Oncol. 2025;15:1642833.

PubMed: <https://www.amedeo.com/p2.php?id=41049855&s=blc&pm=1462f940041c1dd>

ABSTRACT available

Share: <https://m.amedeo.com/41049855>

23. GUI Q, Guo H, Liu T, Wen X, et al.

Prognostic risk factors and the role of systemic inflammatory response index in

predicting outcomes for non-muscle-invasive bladder cancer.

Front Oncol. 2025;15:1646723.

PubMed: <https://www.amedeo.com/p2.php?id=41049840&s=blc&pm=1462f940041c1dd>

ABSTRACT available

Share: <https://m.amedeo.com/41049840>

24. CHOU KY, Chang AC, Hwang TI, Tsai TF, et al.

ABCC6 Transporter Contributed to Cisplatin Resistance on Bladder Cancer.

Int J Med Sci. 2025;22:3895-3905.

PubMed: <https://www.amedeo.com/p2.php?id=41049434&s=blc&pm=1462f940041c1dd>

ABSTRACT available

Share: <https://m.amedeo.com/41049434>

25. DI Y, Zhang L, Zhao L, Yin L, et al.

Influencing Factors and Risk Prediction Model Construction of Urinary Tract

Infections in Patients with Bladder Cancer.

Res Rep Urol. 2025;17:383-399.

PubMed: <https://www.amedeo.com/p2.php?id=41048480&s=blc&pm=1462f940041c1dd>

ABSTRACT available

Share: <https://m.amedeo.com/41048480>

26. PECE A, Lovato G, Cela I, Mercatelli A, et al.

Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a

novel urinary disease biomarker.

Mol Oncol. 2025 Oct 5. doi: 10.1002/1878-0261.70140.

PubMed: <https://www.amedeo.com/p2.php?id=41046347&s=blc&pm=1462f940041c1dd>

ABSTRACT available

Share: <https://m.amedeo.com/41046347>

27. CHEN AL, Zhang CA, Ogunkeye J, Ge TJ, et al.

Differences in postoperative communication patterns among patients with limited

English proficiency following radical cystectomy for bladder cancer.

Urol Oncol. 2025 Oct 3:S1078-1439(25)00346-1. doi: 10.1016/j.urolonc.2025.

PubMed: <https://www.amedeo.com/p2.php?id=41046200&s=blc&pm=1462f940041c1dd>

ABSTRACT available

Share: <https://m.amedeo.com/41046200>

28. MOHAMMADNEJAD F, Rajabi N, Doustvandi MA, Nobari SA, et al.

Photodynamic therapy with zinc phthalocyanine enhances cisplatin sensitivity of

human muscle-invasive bladder cancer cells by downregulation of PI3K/AKT/mTOR

signaling pathway.

Cancer Treat Res Commun. 2025;45:101007.

PubMed: <https://www.amedeo.com/p2.php?id=41045729&s=blc&pm=1462f940041c1dd>

ABSTRACT available

Share: <https://m.amedeo.com/41045729>

29. LONGONI M, Falkenbach F, Marmiroli A, Le QC, et al.

Effect of neoadjuvant chemotherapy on years of life lost in radical

cystectomy-treated T2N0M0 bladder cancer patients.

World J Urol. 2025;43:591.

PubMed: <https://www.amedeo.com/p2.php?id=41045402&s=blc&pm=1462f940041c1dd>

ABSTRACT available

Share: <https://m.amedeo.com/41045402>

30. LOTEM M, Sharkia I, Azria B, Harpenas E, et al.

Urine cf-nucleosomes: A non-invasive window into human physiology and disease.

Cell Genom. 2025;5:100974.

PubMed: <https://www.amedeo.com/p2.php?id=40816280&s=blc&pm=1462f940041c1dd>

ABSTRACT available

Share: <https://m.amedeo.com/40816280>

31. BROUZES H, Ourfali S, Fassi-Fehri H, Benoit-Janin M, et al.

Predicting recurrence and progression in NMIBC: A multi-event and temporal

analysis approach.

Fr J Urol. 2025;35:102921.

PubMed: <https://www.amedeo.com/p2.php?id=40550272&s=blc&pm=1462f940041c1dd>

ABSTRACT available

Share: <https://m.amedeo.com/40550272>

32. IIZUKA T, Ishikawa A, Motoi N, Kanda H, et al.

Immunostaining for polycomb group protein EZH2 as a diagnostic tool to

differentiate urothelial carcinoma in situ from benign lesions.

Hum Pathol. 2025;160:105823.

PubMed: <https://www.amedeo.com/p2.php?id=40456417&s=blc&pm=1462f940041c1dd>

ABSTRACT available

Share: <https://m.amedeo.com/40456417>

33. WU J, Cheng B, Song Y, Cheng J, et al.

Targeting Sialylation Enhances the Therapeutic Efficacy of the Nectin-4-Targeted

Antibody-Drug Conjugate Enfortumab Vedotin in Bladder Cancer.

Cancer Res. 2025 Oct 9. doi: 10.1158/0008-5472.CAN-25-0024.

PubMed: <https://www.amedeo.com/p2.php?id=41066596&s=blc&pm=1462f940041c1dd>

ABSTRACT available

Share: <https://m.amedeo.com/41066596>

34. PRADERE B, Schuit M, Guerrero-Ramos F, Shariat SF, et al.

Side effect management and procedural best practices with indwelling intravesical

drug-releasing systems in the treatment of bladder cancer: recommendations from

expert panels.

Curr Opin Urol. 2025 Oct 8. doi: 10.1097/MOU.0000000000001350.

PubMed: <https://www.amedeo.com/p2.php?id=41065373&s=blc&pm=1462f940041c1dd>

ABSTRACT available

Share: <https://m.amedeo.com/41065373>

35. DANESHMAND S, Zaucha R, Catto JWF, Tran B, et al.

Erdafitinib in Patients with High- and Intermediate-risk Non-muscle-invasive

Bladder Cancer: Final Analysis of THOR-2 Study.

Eur Urol. 2025 Oct 7:S0302-2838(25)04702-5. doi: 10.1016/j.eururo.2025.09.4152.

PubMed: <https://www.amedeo.com/p2.php?id=41062389&s=blc&pm=1462f940041c1dd>

ABSTRACT available

Share: <https://m.amedeo.com/41062389>

36. KWONG JCC, Al-Daqqaq Z, Chelliahpillai Y, Lee S, et al.

Development and International Evaluation of an Artificial Intelligence-based

Model (PROGRxN-BCa) Using the World Health Organization 2004/2022 Grading System

to Predict Progression Risk and Improve Substratification for Non-muscle-invasive

Bladder Cancer.

Eur Urol. 2025 Oct 7:S0302-2838(25)04688-3. doi: 10.1016/j.eururo.2025.09.4145.

PubMed: <https://www.amedeo.com/p2.php?id=41062388&s=blc&pm=1462f940041c1dd>

ABSTRACT available

Share: <https://m.amedeo.com/41062388>

37. MEGHANI K, Yu Y, Frydenlund N, Li EZ, et al.

Genomic and Transcriptomic Profiling of High-risk Bladder Cancer Reveals Diverse

Molecular and Microenvironment Ecosystems.

Eur Urol. 2025 Oct 6:S0302-2838(25)04677-9. doi: 10.1016/j.eururo.2025.09.4138.

PubMed: <https://www.amedeo.com/p2.php?id=41058365&s=blc&pm=1462f940041c1dd>

ABSTRACT available

Share: <https://m.amedeo.com/41058365>

38. INOUE S, Hayakawa A, Kobayashi M, Nagasaka Y, et al.

Response to First-Line Chemotherapy Predicts Response to Maintenance Avelumab

Therapy in Japanese Patients With Advanced Urothelial Carcinoma.

Int J Urol. 2025;32:1449-1459.

PubMed: <https://www.amedeo.com/p2.php?id=40600395&s=blc&pm=1462f940041c1dd>

ABSTRACT available

Share: <https://m.amedeo.com/40600395>

39. AKPINAR C, Erkartal S, Soydas T, Demirel D, et al.

Decision Curve Analysis-Based Risk-Adaptive Strategy for Individualizing

Cystoscopy Decisions in Patients With Primary Microscopic Hematuria.

Int J Urol. 2025;32:1395-1402.

PubMed: <https://www.amedeo.com/p2.php?id=40528720&s=blc&pm=1462f940041c1dd>

ABSTRACT available

Share: <https://m.amedeo.com/40528720>

40. MEEKS JJ, van der Heijden MS, Powles T, Galsky MD, et al.

PD37-09 The First Report Of Disease-Free Survival Analyses From The Niagara Trial

Of Perioperative Durvalumab Plus Neoadjuvant Chemotherapy In Muscle-Invasive

Bladder Cancer: Erratum.

J Urol. 2025;214:556.

PubMed: <https://www.amedeo.com/p2.php?id=41065094&s=blc&pm=1462f940041c1dd>

Share: <https://m.amedeo.com/41065094>

41. DONAHUE TF, Assel M, Cha EK, Goh A, et al.

Evaluating Benefits of Peristomal Mesh Placement at the Time of Radical

Cystectomy and Ileal Conduit Formation: A Phase 3, Randomized Controlled Trial.

J Urol. 2025;214:487-495.

PubMed: <https://www.amedeo.com/p2.php?id=40779615&s=blc&pm=1462f940041c1dd>

ABSTRACT available

Share: <https://m.amedeo.com/40779615>

42. YEH CC, Tsai PC, Song YD, Low YS, et al.

Metformin as an anti-cancer agent against bladder cancer acts via PD-L1

downregulation in an orthotopic mouse model.

BMC Cancer. 2025;25:1534.

PubMed: <https://www.amedeo.com/p2.php?id=41063036&s=blc&pm=1462f940041c1dd>

ABSTRACT available

Share: <https://m.amedeo.com/41063036>

43. KANAAN MR, Schmitz J, Braesen JH, Kuczyk MA, et al.

Comparison of molecular profiles (Nectin-4 and TROP-2) in upper tract urothelial

carcinoma with a positive history of urinary bladder cancer vs. UTUC only in the

era of ADCs.

BMC Cancer. 2025;25:1525.

PubMed: <https://www.amedeo.com/p2.php?id=41053655&s=blc&pm=1462f940041c1dd>

ABSTRACT available

Share: <https://m.amedeo.com/41053655>

44. ABOULHODA BE, Omar AM, Elfarrash S, Alghamdi MA, et al.

Novel anticancer effect of substituted imidazole derivatives against urothelial

carcinoma: integrating In vitro screening and molecular docking for target

kinases.

BMC Cancer. 2025;25:1524.

PubMed: <https://www.amedeo.com/p2.php?id=41053651&s=blc&pm=1462f940041c1dd>

ABSTRACT available

Share: <https://m.amedeo.com/41053651>

\*\*\* End \*\*\*

You subscribed to this newsletter on 2004-11-19.

If you want to unsubscribe from this Amedeo newsletter, please open the

following link and click on the Unsubscribe button:

<https://www.amedeo.com/user/uiu.php?code=ib9f5b7a5f565&cid=267327>